STING agonist ADC (Ryvu Therapeutics/Exelixis)

N/A

Report date: 2025/06/11 11:01:58

Base Information

Drug NameSTING agonist ADC (Ryvu Therapeutics/Exelixis)
Drug Alias NameSTING agonist antibody-drug conjugate (Ryvu Therapeutics/Exelixis)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionT lymphocytes stimulantsStimulator of interferon genes stimulantsDendritic cells stimulants +[4] 
TargetsStimulator of interferon genes
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPoland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRyvu Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesExelixis Inc
Inactive CompaniesRyvu Therapeutics Sa
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A